Slides current until 2008 Diabetic nephropathy. Curriculum Module III-7b Slide 2 of 37 Slides current until 2008 Risk factors Poor glycaemic control Hyperlipidaemia.

Slides:



Advertisements
Similar presentations
Chronic kidney disease
Advertisements

Slides current until 2008 Nutritional needs of people with type 1 diabetes and type 2 diabetes.
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Dinkar Kaw, M.D., Division of Nephrology
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
The PREVEND Study: Screening for micro-albuminuria
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
DIABETES AND THE KIDNEYS
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
DM & CKD Dr. Shahrzad Shahidi Professor of Nephrology Isfahan University of Medical Sciences.
RENAL BLOOD TESTS WHAT DO THEY MEAN, WHERE TO GO FOR WHAT TO DO.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Lesley Stevens MD Tufts-New England Medical Center
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Complications of diabetes mellitus Ceri Jones Cwm Taf University LHB 2014.
CHRONIC KIDNEY FAILURE
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
1 Diabetes Education Teaching Guide Kidney Health.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
Microvascular complications Diabetes Outreach (August 2011)
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.
CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Shadi Al-Ahmadi. The Presentation will include: Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic.
Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Section 5: Configuration of healthcare to manage CKD.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Glucose Control and Monitoring
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Kimberly Dunbar, PA-S2 Follow-up of Cardiovascular Risk Markers in Hypertensive Patients Treated with Irbesartan: Results of the i-SEARCH Plus Registry.
2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
CHRONIC KIDNEY DISEASE
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
Renal Complications Associated with Diabetes By Gabriella Benavides FNP-BC.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
The Significance of Albuminuria
Section 4: Managing progression of CKD
Darshika Chhabra, MD, MPH
HOPE: Heart Outcomes Prevention Evaluation study
Dr. Mohammad Alkhowaiter, MD Consultant Nephrologist
Diabetes Health Status Report
So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.
Chronic Kidney Disease
Section I: RAS manipulation
American Journal of Kidney Diseases
Presentation transcript:

Slides current until 2008 Diabetic nephropathy

Curriculum Module III-7b Slide 2 of 37 Slides current until 2008 Risk factors Poor glycaemic control Hyperlipidaemia Hypertension Genetic predisposition Glomerular hyper-filtration during early period Ethnicity Long disease duration Smoking

Diabetic nephropathy Curriculum Module III-7b Slide 3 of 37 Slides current until 2008 Diabetic nephropathy About 20% to 30% of people with diabetes In type 2 diabetes, a smaller fraction of these progress to CKD People with type 2 diabetes – over half of those with diabetes starting on dialysis

Diabetic nephropathy Curriculum Module III-7b Slide 4 of 37 Slides current until 2008 Type 1 diabetes Decreasing incidence over past 35 years Overall incidence –2.2% at 20 years duration –7.8% at 30 years duration Finne 2005

Diabetic nephropathy Curriculum Module III-7b Slide 5 of 37 Slides current until 2008 Microalbuminuria (incipient diabetic nephropathy) Acute renal hypertrophy-hyperfunction Normoalbuminuria Proteinuria (clinical overt diabetic nephropathy) Chronic renal failure 10 to 15 years Natural history of diabetic nephropathy

Diabetic nephropathy Curriculum Module III-7b Slide 6 of 37 Slides current until 2008 Protein Albumin Albumin Excretion Rate Microalbuminuria: mg/24 hr µg/min mg/mmol (men) mg/mmol (women) Macroalbuminuria: >300 mg/24 hr or >200 µg/min >25 mg/mmol (men) >35 mg/mmol (women) Protein, microalbuminuria and macroalbuminuria

Diabetic nephropathy Curriculum Module III-7b Slide 7 of 37 Slides current until 2008 Transient increases in albumin excretion Exercise Menstruation Pregnancy Poor glycaemic control Urinary tract infection Hypertension Cardiac failure Factors affecting albumin excretion

Diabetic nephropathy Curriculum Module III-7b Slide 8 of 37 Slides current until 2008 Transient microalbuminuria 2/874/879/871/882/884/885/888/882/897/89 10/89 1/905/907/90 10/90 2/92 6/91 10/91 4/ µg/min 15 µg/min AER (µg/min x 1,73m²) Age: 15 years diabetes duration: 5 years Girl >2 consecutive measurements >20 µg/min therafter 3 measurements normal Example:

Diabetic nephropathy Curriculum Module III-7b Slide 9 of 37 Slides current until 2008 Permanent microalbuminuria 8/87 10/8811/8812/88 4/891/907/909/90 10/9012/90 9/91 11/9212/93 6/947/ µg/min 15 µg/min Age: 21 years diabetes duration: 10 years Girl AER (µg/min x 1,73m²) 3 consecutive measurements >20 µg/min Example:

Diabetic nephropathy Curriculum Module III-7b Slide 10 of 37 Slides current until 2008 Diabetic renal assessment Urinalysis for proteinuria Spot urine for microalbuminuria –morning and resting or –preferably with albumin/creatinine ratio (normal <2.5 mg/mmol in men and <3.5 mg/mmol in women) Serum creatinine; preferably with adjustment of body size Calculated glomerular filtration rate Repeat the tests at about yearly intervals if normal If GFR <60 ml/min test 3-6 monthly

Diabetic nephropathy Curriculum Module III-7b Slide 11 of 37 Slides current until 2008 Microalbuminuria Type 1 diabetes –indicates incipient nephropathy Type 2 diabetes –marker of increased cardiovascular morbidity and mortality Presence of microalbuminuria is an indication for screening of vascular disease and intensive intervention

Diabetic nephropathy Curriculum Module III-7b Slide 12 of 37 Slides current until 2008 Interventions: glycaemic control Diabetes Control and Complications Trial (DCCT) – occurrence of microalbuminuria by 40% – occurrence of macroalbuminuria by 50% United Kingdom Prospective Diabetes Study (UKPDS) – overall microvascular complication rate by 25%

Diabetic nephropathy Curriculum Module III-7b Slide 13 of 37 Slides current until 2008 Institution of tight metabolic control after onset of overt proteinuria or renal insufficiency is important for general health but not all that helpful in preventing chronic kidney disease.

Diabetic nephropathy Curriculum Module III-7b Slide 14 of 37 Slides current until 2008 Diabetic nephropathy Treatment –intensive treatment of blood pressure target <130/80 mmHg –reduce salt in diet –reduce alcohol Sacks, 2001

Diabetic nephropathy Curriculum Module III-7b Slide 15 of 37 Slides current until 2008 Interventions: hypertension control Type 1 diabetes Lewis Study (Collaborative Study Group) –proteinuria –captopril  albumin excretion rate – in rate of decline of kidney function by 30% ACE inhibitors have independent effect Lewis et al 1993

Diabetic nephropathy Curriculum Module III-7b Slide 16 of 37 Slides current until 2008 Interventions: hypertension control Type 2 diabetes IRMA 2 –(microalbuminuria) IDNT –(proteinuria) IRMA 2 + IDNT = PRIME –angiotensin-2 receptor blockers (Irbesartan) –reduced progression by 30%

Diabetic nephropathy Curriculum Module III-7b Slide 17 of 37 Slides current until 2008 Interventions: hypertension control Any blood pressure-reducing medication can be used Often need at least three agents

Diabetic nephropathy Curriculum Module III-7b Slide 18 of 37 Slides current until 2008 Management of people with elevated creatinine Caution should be taken when using the following: –metformin –non-steroidal anti-inflammatory drugs –glibenclamide –radiographic contrast

Diabetic nephropathy Curriculum Module III-7b Slide 19 of 37 Slides current until 2008 Management of people with elevated creatinine Insulin dosage may need adjustment due to change in insulin half life and dialysis Anaemia is common and may need treatment – measure haemoglobin every 6 months if eGFR is <60 ml/min/1.73 m 2 Refer to nephrologist when eGFR <30 ml/min/1.73m 2

Diabetic nephropathy Curriculum Module III-7b Slide 20 of 37 Slides current until 2008 CKD – clinical features Nausea Poor appetite and weight loss Fatigue Dry, itchy skin Oedema Anaemia Dyspnea   serum creatinine   GFR

Diabetic nephropathy Curriculum Module III-7b Slide 21 of 37 Slides current until 2008 Nutritional needs As renal failure progresses Recommended diet may change over time Fluid restriction at renal failure Evidence base weak for protein restriction in diabetes

Diabetic nephropathy Curriculum Module III-7b Slide 22 of 37 Slides current until 2008 Estimated Glomerular Filtration Rate (eGFR) May underestimate actual renal function especially in women, the young and the obese More accurate in lower ranges <60 ml/min If eGFR is <60 ml/min, 30% risk of CVD Most common cause of death in CKD is cardiac arrest (22%)

Diabetic nephropathy Curriculum Module III-7b Slide 23 of 37 Slides current until 2008 Estimated Glomerular Filtration Rate (eGFR) <60 ml/min – osteodystrophy – anaemia <30 ml/min – pre-dialysis < 15 ml/min – dialysis and transplant

Diabetic nephropathy Curriculum Module III-7b Slide 24 of 37 Slides current until 2008 Treatment of chronic kidney disease (CKD) Prepare for eventual dialysis Peritoneal dialysis Haemodialysis Renal transplantation

Diabetic nephropathy Curriculum Module III-7b Slide 25 of 37 Slides current until 2008 Peritoneal (PD) versus haemodialysis (HD) PDHD Time hr/treatment treatment/week 24 hr continuous or >10 hr overnight 7 days per week Dialysis Solution duration 8-15 l per day (3-5 h) ml minutes for treatment Volume Dialysis solution Delivery system 2-3 l per exchangecontinuous flow AccessPD cathetervascular catheter, fistula or graft

Diabetic nephropathy Curriculum Module III-7b Slide 26 of 37 Slides current until 2008 Management of hyperglycaemia, CKD and dialysis Blood glucose-lowering agents Subcutaneous insulin Intraperitoneal insulin – more consistent, physiological absorption

Diabetic nephropathy Curriculum Module III-7b Slide 27 of 37 Slides current until 2008 Special problems in peritoneal dialysis Catheter-related infection Risk of peritonitis Glucose absorption from peritoneal dialysis fluid may affect glycaemic control WARNING: Check the meter used with peritoneal dialysis

Diabetic nephropathy Curriculum Module III-7b Slide 28 of 37 Slides current until 2008 Special problems in hemodialysis Vascular access problem Hypotension Advanced cardiac disease Pre-dialysis hyperkalemia Hypoglycaemia

Diabetic nephropathy Curriculum Module III-7b Slide 29 of 37 Slides current until 2008 Renal transplant Discuss the use of renal transplantation in your country. ACTIVITY

Diabetic nephropathy Curriculum Module III-7b Slide 30 of 37 Slides current until 2008 Summary Diabetes is a common cause of CKD Various grades of nephropathy The higher the A 1c the higher the risk Control matters Blood pressure

Diabetic nephropathy Curriculum Module III-7b Slide 31 of 37 Slides current until 2008 Review question 1.Which of the following statements concerning the development of microalbuminuria and hypertension in people with diabetes is true? a.In type 1 diabetes, hypertension is usually not present until several years after microalbuminuria is detected b.In type 2 diabetes, hypertension is often present on diagnosis but microalbuminuria is usually not detected until 10 to 20 years after diagnosis c.In type 1 diabetes, hypertension and microalbuminuria are often detected at about the same time d.In type 2 diabetes, both hypertension and microalbuminuria tend to appear after insulin therapy is initiated

Diabetic nephropathy Curriculum Module III-7b Slide 32 of 37 Slides current until 2008 Review question 2. Which of the following people with diabetes should have a urine screening test for microalbuminuria: a.A man who is newly diagnosed with type 1 diabetes b.A woman with type 1 diabetes for 2 years, who presently has blood glucose levels over 20mmol/L c.A woman with type 2 diabetes who has had macroalbuminuria detected twice on recent routine urinalysis d.A man who is newly diagnosed with type 2 diabetes and has no protein detected on routine urinalysis

Diabetic nephropathy Curriculum Module III-7b Slide 33 of 37 Slides current until 2008 Review question 3. In the UKPDS, improving blood glucose levels through intensive diabetes management significantly decreased the risk of: a.Nephropathy b.Hypertension c.Myocardial infarction d.Stroke

Diabetic nephropathy Curriculum Module III-7b Slide 34 of 37 Slides current until 2008 Review question 4. When overt nephropathy is approaching ESRD, what information would be accurate regarding insulin requirements? a.Kidney failure often decreases insulin requirements b.Kidney failure has no effect on insulin needs until people are on dialysis c.Kidney failure most often increases the requirement of long-acting insulin d.Kidney failure increases the need for rapid-acting insulin

Diabetic nephropathy Curriculum Module III-7b Slide 35 of 37 Slides current until 2008 Answers 1.c 2.d 3.a 4.a

Diabetic nephropathy Curriculum Module III-7b Slide 36 of 37 Slides current until 2008 References 1.Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–86. 2.Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210–7. 3.Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and Diabetes Care 1978; 1: 168–88. 4.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53. 5.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: International Diabetes Federation - The Kidney Issue. Diabetes Voice 2003; 48: Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl 2): S The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients of high risk of cardiovascular events. Can J Cardiol 1996; 12:

Diabetic nephropathy Curriculum Module III-7b Slide 37 of 37 Slides current until 2008 References 9.Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group (published erratum appears in N Eng J Med 1993; 330: 152). N Eng J Med 1993; 329: Andersen S, Brochner-Morteusen J, Parving H. Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in patients with type 2 diabetes and Microalbuminuria. Diabetes Care 2003; 26(12): Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294(14): IDF Clinical Guidelines Task Force. Global Guideline for type 2 diabetes. Brussels: International Diabetes Federation Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1): Berl T, Hunsicker LG, Lewis JB, et al. for the Collaborative Study Group* Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy. Ann Intern Med 2003; 138: